Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes


Link to publication record in Ulster University Research Portal

Published in:
Journal of Endocrinology

Publication Status:
Published (in print/issue): 01/04/2020

DOI:
10.1530/JOE-19-0451

Document Version
Author Accepted version

General rights
Copyright for the publications made accessible via Ulster University's Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Ulster University's institutional repository that provides access to Ulster's research outputs. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact pure-support@ulster.ac.uk.
Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes

Neil Tanday, Peter R. Flatt, Nigel Irwin*, R. Charlotte Moffett

From the SAAD Centre for Pharmacy and Diabetes, Ulster University, Coleraine, Northern Ireland, UK.

*Address correspondence and reprint requests to: Nigel Irwin, SAAD Centre for Pharmacy and Diabetes, Ulster University, Coleraine, Northern Ireland, UK. E-mail: n.irwin@ulster.ac.uk. Tel: ++44 (0) 28 70 124754.

Short title: Islet-cell transdifferentiation in diabetes

Keywords: Diabetes, dipeptidyl peptidase-4 (DPP-4), glucagon-like peptide-1 (GLP-1), high fat feeding (HFF), hydrocortisone (HC), streptozotocin (STZ), islets, beta-cell, transdifferentiation
Abstract

Transdifferentiation of beta- to alpha-cells has been implicated in the pathogenesis of diabetes. To investigate the impact of contrasting aetiologies of beta-cell stress, as well as clinically approved incretin therapies on this process, lineage tracing of beta-cells in transgenic $\text{Ins1}^{\text{Cre+/+}}$/$\text{Rosa26-eYFP}$ mice was investigated. Diabetes-like syndromes were induced by streptozotocin (STZ), high fat feeding (HFF) or hydrocortisone (HC), and effects of treatment with liraglutide or sitagliptin investigated. Mice developed the characteristic metabolic features associated with beta-cell destruction or development of insulin resistance. Liraglutide was effective in preventing weight gain in HFF mice, with both treatments decreasing energy intake in STZ and HC mice. Treatment intervention also significantly reduced blood glucose levels in STZ and HC mice, as well as increasing either plasma or pancreatic insulin while decreasing circulating or pancreatic glucagon in all models. The recognised changes in pancreatic morphology induced by STZ, HFF or HC were partially, or fully, reversed by liraglutide and sitagliptin, and related to advantageous effects on alpha- and beta-cell growth and survival. More interestingly, induction of diabetes-like phenotype, regardless of pathogenesis, led to increased numbers of beta-cells losing their identity, as well as decreased expression of Pdx1 within beta-cells. Both treatment interventions, and especially liraglutide, countered detrimental islet cell transitioning effects in STZ and HFF mice. Only liraglutide imparted benefits on beta- to alpha-cell transdifferentiation in HC mice. These data demonstrate that beta- to alpha-cell transdifferentiation is a common consequence of beta-cell destruction or insulin resistance, and that clinically approved incretin-based drugs effectively limit this.
**Introduction**

The pathogenesis of diabetes is complex, involving many processes that ultimately results in pancreatic beta-cell dysfunction and/or development of peripheral insulin resistance [Weir et al. 2004]. The deficit of beta-cell mass and function in diabetes is not well understood, and has been linked to a loss of beta-cell identity, but related mechanism prove difficult to investigate [Accili et al. 2010; Kitamura, 2013]. However, recent advances in cell lineage tracing technologies has shed light on the process of pancreatic beta-cells transitioning from their mature state to become dedifferentiated or transdifferentiated into other cell types [Collombat et al. 2007; 2009; Thorel et al. 2010; Huising et al. 2018]. As such, beta-cell dedifferentiation is defined as a loss of beta-cell components, usually associated with an increase in the expression of progenitor markers, resulting in reduced insulin secretion [Weir et al. 2013]. The related process of transdifferentiation is generally categorised as a fully differentiated islet cell, such as a beta-cell, losing its phenotype and converting to an entirely new islet endocrine like cell [Talchai et al. 2012; Rutter et al. 2015]. This process can occur directly, when an islet cell demonstrates a second hormone before losing expression of its initial hormone, or indirectly whereby an intermediate dedifferentiation stage occurs prior to transition to a new islet cell [van der Meulen and Huising, 2015].

Extreme experimental conditions can been used to provoke and study transdifferentiation of islet cells in rodents. This includes chemically-induced beta-cell ablation [Thorel et al. 2010] or through altering the expression of specific islet cell transcription factors such as aristaless-related homeobox (Arx) [Courtney et al. 2013], paired box gene 4 (Pax4) [Collombat et al. 2007], pancreatic and duodenal homeobox 1 (Pdx-1) or forkhead box O1 (FOXO1) [Talchai et al. 2012]. Expression of such transcription factors are known to be vital in maintaining differentiated islet cell phenotypes [Gu et al. 2010; Gao et
al. 2014; Taylor et al. 2015; Hart et al. 2015]. As such, natural loss of beta-cell FOXO1 expression during aging results in increased susceptibility to diabetes due to beta-cell dedifferentiation [Kitamura et al. 2013]. Importantly, these processes are not restricted to rodents, with dedifferentiation and transdifferentiation being observed in vitro in human beta-cells [Gershengorn, et al. 2004; Weinberg et al. 2007; Spikjer et al. 2013; Diedisheim et al. 2018] and in islet cells harvested directly from type 2 diabetes mellitus (T2DM) patients [Cinti et al. 2015].

In this regard, beneficial effects of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), in T2DM have been linked to direct positive effects at the level of the endocrine pancreas. This includes, but not limited to, potentiation of glucose-stimulated insulin secretion, promotion of beta-cell growth, protection of beta cells from apoptosis and, in the case of GLP-1, suppression of glucagon secretion [Mest et al. 2005; Baggio and Drucker, 2007]. In addition, incretin peptides have been shown to upregulate expression levels of islet cell transcription factors involved in maintenance of beta-cell identity [Wei & Hong, 2019]. Thus, preliminary studies have examined the effects of GLP-1, but not GIP, on islet cell transdifferentiation in diabetes [Wei & Hong, 2019], with suggestion of favourable outcomes. To fully address this concept, the current study has employed transgenic $\text{Ins}1^{\text{Cre}+}/\text{Rosa26-eYFP}$ mice [Thorens et al. 2015] to directly investigate beta- to alpha-cell transdifferentiation under contrasting diabetes-like aetiologies, including multiple low dose streptozotocin (STZ) or hydrocortisone (HC) administration, as well as prolonged high fat feeding. In addition, we also explored the impact of pharmacological upregulation of incretin receptor signalling pathways in each rodent model, through sub-chronic administration of the clinically approved GLP-1 receptor agonist, liraglutide, or the didpeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin. Together these studies unequivocally demonstrate the consequence of diabetes on islet cell
differentiation and the potential beneficial role of incretin receptor signalling on these processes.

Material and Methods

Animals

Ins1\textsuperscript{Cre}/+\textit{Rosa26-eYFP} C57BL/6 mice (Jackson Laboratories, Maine, USA) were bred in house at the Biomedical and Behavioural Research Unit (BBRU) at Ulster University, Coleraine. The original background of these mice has been characterised by Thorens \textit{et al.} [2015]. Mice were housed individually in a temperature controlled room (22±2°C) on a regular 12 hour light/dark cycle. Standard chow (Trouw Nutrition, Norwich, UK) and drinking water were available \textit{ad libitum}. All \textit{in vivo} experiments were approved by Ulster University Animal Ethics Review Committee and conducted in accordance to the UK Animals (Scientific Procedures) Act 1986. Diabetes-like symptoms were induced in male mice (n=6) using STZ, HC or high fat feeding. Our studies were appropriately powered (n=6) to ensure robust and reproducible findings, using minimal numbers of animals, in line with the guiding principles of more ethical use of animals in research. In brief, STZ (50 mg/kg) was given to 12 week old mice on 5 consecutive days by intraperitoneal (i.p.) injection in citrate buffer, inducing symptoms of insulin deficiency 5 days after the final injection. HC (70 mg/kg) was administered to 12 week old mice on 10 consecutive days by i.p. injection, to induce insulin resistance. In both models, twice daily i.p. administration of liraglutide (25 nmol/kg) or once daily oral administration of sitagliptin (50 mg/kg) was commenced 2-3 days prior to administration of STZ or HC and continued until the end of the respective study period. For high-fat feeding studies, 4 week old mice were maintained on a high fat diet (45% fat) until 15 weeks of age to induce obesity and insulin resistance. These mice were similarly dosed with liraglutide (25
nmol/kg, i.p.; BID) or sitagliptin (50 mg/kg, p.o.) for an additional 12 days. The doses of liraglutide and sitagliptin were selected on the basis of previous studies [Gault et al. 2015; O’Harte et al. 2018]. For all studies, groups of 6-8 mice were used together with appropriate saline treated controls. Body weight, energy intake and non-fasting blood glucose were determined at regular intervals. Energy intake was assessed by manually determining consumption of respective diet for each mouse, and then using kJ/g energy content to extrapolate energy intake. Blood glucose measured from a tail vein blood spot using an Ascencia Contour Blood Glucose Meter (Bayer Healthcare, Newbury, UK). Terminal blood samples were taken for biochemical analyses and immunohistochemistry.

**Biochemical analyses**

Snap frozen pancreatic tissues were homogenised in acid ethanol (ethanol (75% (v/v) ethanol, 5% (v/v) distilled water and 1.5% (v/v) 12N HCl) and protein extracted in a pH neutral TRIS buffer. Protein content was determined using Bradford reagent (Sigma-Aldrich, Dorset, UK). Plasma and pancreatic insulin content was determined by an in-house insulin radioimmunoassay [Flatt & Bailey 1981]. Plasma and pancreatic glucagon content was determined by ELISA (glucagon chemiluminescent assay, EZGLU-30K, Millipore) following the Manufacturers guidelines.

**Immunohistochemistry**

Upon termination of studies, pancreatic tissues were excised and fixed in 4% PFA for 48 hours at 4°C. Tissues were processed and embedded in paraffin wax blocks using an automated tissue processor (Leica TP1020, Leica Microsystems, Nussloch, Germany) and 5 µm sections were cut on a microtome (Shandon finesse 325, Thermo scientific, UK). For immunohistochemistry, slides were dewaxed by immersion in xylene and rehydrated through
a series of ethanol solutions (100-50%). Heat mediated antigen retrieval was then carried out in citrate buffer. Sections were blocked in 4% BSA solution before 4°C overnight incubation with the following primary antibodies (Table 1), as appropriate, mouse monoclonal anti-insulin (ab6995, 1:400; Abcam), guinea-pig anti-glucagon (PCA2/4, 1:400; raised in-house), rabbit anti-Ki67 (ab15580, 1:500; Abcam), rabbit anti-Pdx1 (ab47267, 1:200; Abcam) and goat anti-GFP antibody (ab5450, 1:1000; Abcam). Following this, slides were rinsed in PBS and incubated for 45 minutes at 37°C with appropriate secondary antibodies (Table 1) including, Alexa Fluor488 goat anti-guinea pig IgG, Alexa Fluor594 goat anti-mouse IgG, Alexa Fluor488 goat anti-rabbit IgG, Alexa Fluor594 goat anti-rabbit IgG or Alexa Fluor488 donkey anti-goat IgG. Slides were finally incubated with DAPI for 15 mins at 37°C, and then mounted for imaging using a fluorescent microscope (Olympus system microscope, model BX51) fitted with DAPI (350 nm) FITC (488 nm) and TRITC (594 nm) filters and a DP70 camera adapter system. As such, DAPI nuclear staining was used to ensure only viable cells were analysed, and exclude artefacts such as cell stacking within our image analysis. To assess cellular apoptosis a TUNEL assay was carried out following the Manufacturer’s guidelines (In situ cell death kit, Fluorescein, Roche Diagnostics, UK).

**Image analysis**

CellF imaging software (Olympus Soft Imaging Solutions, GmbH) was used to analyse the following islet parameters: islet-, beta- and alpha-cell areas. For transdifferentiation, cells expressing GFP with no insulin were termed ‘insulin-ve, GFP+ve’ cells, whilst islet cells co-expressing GFP with glucagon were termed ‘glucagon+ve, GFP+ve’ cells. To quantify apoptosis, beta- and alpha-cells co-expressing TUNEL alongside insulin and glucagon respectively were counted. Similarly, for proliferation, Ki-67 and insulin or glucagon positive cells were recorded. To assess Pdx1 expression, the number of Pdx1/insulin positive cells...
were quantified and expressed as a percentage of total insulin expressing cells. All cell counts were determined in a blinded manner with >60 islets analysed per treatment group.

Statistics

Results were analysed using GraphPad PRISM (version 5), with data presented as mean ± SEM. Comparative analyses between groups were carried out using student’s unpaired t-test, one-way ANOVA with a Bonferroni post-hoc test or a two-way repeated measures ANOVA with a Bonferroni post-hoc test where appropriate. Results were deemed significant once P<0.05.

Results

Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration, on body weight and energy intake in Ins1Cre/+\textit{Rosa26-eYFP} mice

All STZ mice displayed a decline (P<0.001) in body weight and overall percentage body weight change, with the greatest reduction observed in the sitagliptin treated group (Figure 1A,B). All As a result of 15 weeks of high fat feeding prior to experimentation, all HFF mice presented with increased body weight when compared to lean controls (Figure 1D). In terms of percentage change in body weight over the 12-day treatment period, there was no difference between lean and HFF control mice, with only liraglutide significantly (P<0.001) decreasing this parameter (Figure 1E). Body weight was reduced (P<0.001) in HC-treated mice, and liraglutide or sitagliptin had no impact on this (Figure 1G,H). In addition, STZ mice exhibited decreased (P<0.05 – P<0.001) cumulative energy intake from day 4 onwards, with a further reduction (P<0.05 – P<0.001) evoked by treatment with liraglutide or sitagliptin (Figure 1C). Energy intake was consistently increased (P<0.05 – P<0.001) in HFF
mice, and liraglutide had a tendency to decrease this, but as with sitagliptin, was without
significant effect (Figure 1F). HC mice presented with significantly (P<0.05) increased
ergy intake on days 9 and 10, with significant (P<0.001) reductions induced by both
liraglutide and sitagliptin treatments (Figure 1I).

**Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or
sitagliptin administration, on blood glucose as well as plasma and pancreatic insulin and
glucagon in Ins1\(^{Cre/+}\)/Rosa26-eYFP mice**

STZ mice exhibited increased blood glucose from day 7 onwards, attaining concentrations of
26.3 ± 1.4 vs. 8.3 ± 0.3 mmol/l in lean control mice by day 10 (Figure 2A). HFF and HC mice
had no substantial change in blood glucose levels (Figure 2B-D). However, treatment with
liraglutide or sitagliptin significantly (P<0.05 – P<0.001) reduced blood glucose levels in
STZ and HC, but not HFF, mice (Figure 2A-D). In STZ mice, plasma (P<0.01) and
pancreatic (P<0.001) insulin were reduced, with both incretin therapies returning these
parameters to lean control levels (Figure 2E,F). High fat feeding increased (P<0.01) plasma
insulin (Figure 2E), whilst both incretin therapies increased (P<0.001) pancreatic insulin
content in HFF mice (Figure 2F). In HC mice, plasma and pancreatic insulin were both raised
(P<0.01) with sitagliptin therapy further enhancing (P<0.05) plasma insulin (Figure 2E), and
liraglutide reducing (P<0.01) pancreatic insulin (Figure 2F). Plasma glucagon was raised
(P<0.05 – P<0.001) in all three mouse models (Figure 2G). Liraglutide significantly (P<0.01)
reduced circulating glucagon levels in STZ and HFF mice, whereas sitagliptin elicited a
decrease in HFF (P<0.01) and HC (P<0.05) mice (Figure 2G). Similarly, liraglutide fully, and
sitagliptin partially, countered the elevated glucagon in STZ diabetes (Figure 2H). Liraglutide
was also able to reduce (P<0.01) pancreatic glucagon in HC mice (Figure 2H).
Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration, on pancreatic islet morphology in Ins1\textsuperscript{Cre/+}/Rosa26-eYFP mice

STZ mice displayed reduced (P<0.01) islet and beta-cell areas (Figure 3A,B), accompanied by increased (P<0.001) alpha-cell area (Figure 3C). Islet area in liraglutide (P<0.01) and sitagliptin (P<0.05) treated STZ mice was elevated, despite no significant differences in alpha- or beta-cell mass (Figure 3A-C). HFF mice presented with increases in islet, beta- and alpha-cell areas (Figure 3A-C). Sitagliptin elicited significant (P<0.05 – P<0.01) reductions in these three islet parameters (Figure 3A-C). Liraglutide treatment only reduced (P<0.05) beta-cell area (Figure 3B). HC mice had increased islet (P<0.01) and beta-cell (P<0.001) areas, with no change in alpha-cell area (Figure 3A-C). Liraglutide did not affect this pattern but sitagliptin treatment resulted in a small expansion (P<0.05) of alpha-cell area (Figure 3C).

Representative images of pancreatic tissue stained fluorescently for insulin, glucagon and DAPI form STZ, HFF and HC diabetic mice Ins1\textsuperscript{Cre/+}/Rosa26-eYFP mice, as well as those mice treated with liraglutide and sitagliptin, are shown in Figure 3D.

Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration, on beta-to-alpha cell transdifferentiation and Pdx1 expression in Ins1\textsuperscript{Cre/+}/Rosa26-eYFP mice

All mouse models exhibited a greater (P<0.001) number of insulin negative, GFP positive cells, as well as glucagon positive, GFP positive islet cells (Figure 4A,B). Liraglutide significantly (P<0.05 - P<0.001) reduced numbers of both islet cell types in STZ and HFF mice, as well as glucagon positive, GFP positive cells in HC mice (Figure 4A,B). Sitagliptin had similar benefits in STZ mice, and also reduced (P<0.01) insulin negative, GFP positive cells in HFF mice (Figure 4A,B). Induction of all forms of diabetes reduced (P<0.001) Pdx1
expression in insulin positive cells (Figure 4C). This detrimental effect was reversed by liraglutide treatment in STZ and HC mice, and Pdx1/insulin co-staining was elevated (P<0.05) by liraglutide in HFF mice (Figure 4C). Sitagliptin also increased (P<0.001) Pdx1/insulin co-staining in STZ mice (Figure 4C). Representative images of islets co-stained with insulin or glucagon and GFP, as well as Pdx1 and insulin are shown in Figure 4D-F.

Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration on alpha- and beta-cell proliferation and apoptosis in \textit{Ins}^{\text{Cre+}}/\textit{Rosa26-eYFP} mice

Each mouse model exhibited increased (P<0.05 – P<0.001) beta- and alpha-cell apoptosis (Figure 5A,B). In terms of beta-cells, liraglutide and sitagliptin therapies significantly (P<0.05 – P<0.001) reduced apoptosis in STZ, HFF and HC mice (Figure 5A). For alpha-cells, only liraglutide reduced apoptotic cell numbers, and this was evident only in STZ (P<0.05) and HC (P<0.001) mice (Figure 5B). Indeed, liraglutide returned alpha-cell apoptosis to lean control levels in STZ mice (Figure 5B). High fat feeding (P<0.01) and HC (P<0.001) increased beta-cell proliferation, whereas STZ (P<0.001) and high fat feeding (P<0.05) increased alpha-cell growth (Figure 6A,B). Liraglutide dramatically increased (P<0.001) beta-cell proliferation in STZ mice, but lacked significant effects in HFF and HC mice (Figure 6A). Sitagliptin did not affect beta-cell proliferation in any of the mice (Figure 6A). However, sitagliptin did significantly decrease (P<0.05) alpha-cell growth in STZ and HFF mice, whereas liraglutide was without significant effect (Figure 6B). Representative images of islets co-stained with TUNEL and insulin (Figure 5C) or glucagon (Figure 5D), as well as Ki-67 with insulin (Figure 6C) or glucagon (Figure 6D) are also shown.

Discussion
All major forms of diabetes are linked to pancreatic beta-cell loss over time, which represents an ideal therapeutic target for this disease [Donath and Halben, 2004; Eizirik et al. 2009]. In this regard, GLP-1 mimetics currently administered to T2DM patients have been shown to increase beta-cell mass in rodents through proliferation and/or neogenesis of beta-cells [Moffett et al. 2014], that is presumably linked to upregulation of important beta-cell transcription factors such as Pdx1 [Li et al. 2005; Yang et al. 2011; Gao et al. 2014]. In addition, inhibition of beta-cell apoptosis is a notable feature of GLP-1 receptor activation at the level of the endocrine pancreas [Farilla et al. 2003; Moffett et al. 2014]. Moreover, recent evidence suggests that GLP-1 could augment the process of alpha- to beta-cell transdifferentiation [Zhang et al. 2019]. Additional studies are required to confirm this therapeutically relevant biological action using appropriate experimental tools such as transgenic $\text{Ins}^{\text{Cre+/Rosa26-eYFP}}$ mice [Thorens et al. 2015]. Further to this, although the sister incretin hormone of GLP-1, namely GIP, also induces notable direct beta-cell benefits [Trumper et al. 2002, Ehses et al. 2002], there is an absence of knowledge on the impact of clinically approved DPP-4 inhibitor drugs, that augment circulating levels of GIP and GLP-1, on pancreatic islet cell transdifferentiation.

In the current study, diabetes-like syndromes with contrasting aetiologies were induced in $\text{Ins}^{\text{Cre+/Rosa26-eYFP}}$ mice, through administration of STZ, HC or prolonged high fat (45%) feeding. These transgenic mice displayed the classic features related to either beta-cell destruction or insulin resistance [Vasu et al. 2014]. As expected, the presenting metabolic characteristics and associated pancreatic morphology differed between each mouse model [Vasu et al. 2014]. Thus, STZ mice exhibited hyperglycaemia-insulin deficiency, whereas HFF and HC induced marked hyperinsulinaemia-insulin resistance. All mice consistently exhibited a remarkable increase in the number of pancreatic beta-cells losing their identity, as well as the number of mature insulin-secreting beta-cells transitioning to...
glucagon positive cells. There appeared to a correlation between numbers of insulin negative, GFP positive and glucagon positive, GFP positive islet cells. This suggests that, within the limitations of immunohistochemical co-localisation, a clear islet cell transdifferentiation route seems to exist. This islet cell differentiation effect was consistently associated with decreased beta-cell Pdx1 expression. Such observations clearly indicate that beta-cell dysregulation and insulin resistance are linked to detrimental alteration of pancreatic islet cell differentiation [Talchai et al. 2012], regardless of disease pathogenesis. Given that T2DM patients have low levels of beta-cell apoptosis [Butler et al. 2007], this would suggest that the beta-cell deficit in this disease is connected to beta-cell dedifferentiation or adverse beta-cell transdifferentiation [Huising et al. 2018]. Thus, beta- to alpha-cell transdifferentiation appears to be a normal phenomenon that is amplified in diabetes. The extent to which this amplification process plays in the induction and progression of diabetes still needs to be fully clarified, but our observations suggest at least some involvement. Furthermore, additional studies are required to determine whether the former beta-cells retain the beta-cell glucose sensing behaviour whilst secreting glucagon instead. These factors are of particular relevance in terms of therapeutic interventions, suggesting that antidiabetic drugs positively targeting islet cell differentiation pathways are likely to induce more effective and sustainable benefits in humans.

In all three mouse models both liraglutide and sitagliptin maintained or elevated circulating insulin and decreased plasma glucagon concentrations, while concomitantly reducing blood glucose in STZ and HC mice, in keeping with their notable antidiabetic actions [Drucker and Nauck, 2006]. Lack of obvious effect of liraglutide and sitagliptin on glucose levels in HFF mice is likely related to, absence of hyperglycaemia and the timing of commencement, and duration, of the treatment interventions. As such, treatment was initiated in HFF mice following 15 weeks of high (45%) fat feeding, where obesity, hyperinsulinaemia...
and related insulin resistance were already manifest. In STZ and HC mice, treatment intervention began prior to induction of the diabetes-like phenotypes. It should also be noted that both HFF and HC mice did not present with overt hyperglycaemia, and this is likely due to their prominent hyperinsulinaemia, and related elevated pancreatic beta-cell areas, that was able to offset the recognised insulin resistance in these mouse models [Vasu et al. 2014]. Liraglutide was perhaps more effective in terms of correcting the changes in glucagon, glucose and insulin, and this is could be related to higher circulating GLP-1 levels induced by this treatment regimen [Ghanim et al. 2019]. Indeed, the overall antidiabetic effectiveness of DPP-4 inhibitors is suggested to be slightly less striking than other clinically approved drugs [Rosenstock et al. 2010]. In keeping with this, only liraglutide was able to counter weight gain induced by high fat feeding [Porter et al. 2010], with none of the treatment interventions positively affecting body weight in STZ or HC diabetic mice. This being despite reduced energy intake in liraglutide and sitagliptin treated STZ and HC mice, and no significant impact of the treatments on energy intake in HFF mice. As such, differences in disease aetiologies [Vasu et al. 2014], and the influence and plasticity of GLP-1 receptor activation on central pathways linked to energy homeostasis [Porter et al. 2010], are likely important in accounting for such changes.

Pancreatic islet areas were retuned toward lean control levels by both incretin treatment modalities in STZ and HFF mice, consistent with established antidiabetic efficacy [Vasu et al. 2014]. Interestingly, although STZ and HFF mice had elevated alpha-cell area, pancreatic glucagon concentrations were actually reduced in HFF mice, with sitagliptin inducing a further decrease in both parameters. Similarly, liraglutide and sitagliptin decreased pancreatic glucagon content, without affecting alpha-cell area, in STZ mice. Encouragingly however, both the GLP-1 mimetic and DPP-4 inhibitor drugs decreased circulating glucagon in STZ and HFF mice, in line with beneficial antidiabetic glucagonostatic effects of GLP-1.
receptor activation [Lund et al. 2011]. In addition, liraglutide and sitagliptin increased circulating and pancreatic insulin in both mouse models [Gault et al. 2015; O’Harte et al. 2018], and were especially effective in STZ diabetic mice. Together with decreased glucagon, this could support the notion that incretin receptor activation may prevent or inhibit beta- to alpha-cell transdifferentiation, and foster alpha- to beta-cell transitioning.

Indeed, in STZ mice, both incretin-based treatments limited the number of islet cells converting from beta- to alpha-phenotypes and helped maintain beta-cell identity and maturity by upholding Pdx1 expression [Gao et al. 2014]. Given the similarity in effectiveness of liraglutide and sitagliptin in this regard, it might suggest that increasing GIP alongside GLP-1 provides no additive benefit on islet cell differentiation. However, analysis of circulating concentrations of GIP and GLP-1 would be required to confirm this concept. In addition, islet alpha-cells are known to produce both GLP-1 and GIP under conditions of islet stress [Moffett et al. 2014] and positive effects of sitagliptin within islets cannot be ruled out. Similar favourable observations on differentiation of islet cells were also made in HFF mice treated with liraglutide and sitagliptin, albeit sitagliptin was only capable of provoking non-significant decreases in the number of beta-cells transdifferentiating towards alpha-cells and augmenting Pdx1 expression in beta-cells. Improvements in glycaemic status have been shown to prevent beta-to alpha-cell transdifferentiation as well as reversing beta-cell dedifferentiation [Wang et al. 2014], and importantly islet cell differentiation effects were independent of changes of circulating glucose in HFF mice. Further to this, clear benefits of liraglutide and sitagliptin to inhibit beta-cell apoptosis [Maida et al. 2009; Takeda et al. 2012], as well as promote beta-cell growth in STZ mice [Hendarto et al. 2012], could be important in terms of overall pancreatic architectural effects. However, reduced alpha-cell apoptosis, coupled with unaltered alpha-cell area and proliferation in liraglutide treated STZ
mice, is highly suggestive of alpha- to beta-cell transdifferentiation benefits of this GLP-1 mimetic.

In HC mice, general pancreatic islet architecture was not remarkably altered by concurrent liraglutide or sitagliptin treatment, barring a small increase in alpha-cell area induced by the DPP-4 inhibitor drug. Interestingly, in humans DPP-4 is believed to be expressed at high levels in alpha-cells [Augstein et al. 2015], which may partly explain this finding. However, others have shown the enzyme to be readily expressed in human pancreatic beta-cells, with direct inhibition improving cell function and survival [Bugliani et al. 2018]. Despite this, effects of liraglutide and sitagliptin on islet cell transdifferentiation were minimal in HC mice, aside from the GLP-1 mimetic marginally reducing diabetes-induced loss of beta-cell identity. Liraglutide substantially decreased beta-cell apoptosis in HC mice and augmented Pdx1 expression, but alpha-cell apoptosis was also reduced which may offset this benefit, especially since islet cell proliferation was unaltered by liraglutide. Thus, in this context, incretin type drugs may be less effective for cases of diabetes linked to altered glucocorticoid metabolism [Pivonello et al. 2010]. However, in contrast to this notion, both incretin treatments reduced circulating glucose to levels below that of lean control mice, in keeping with knowledge that glucocorticoids can decrease GLP-1 secretion and action [Van Raalte et al. 2011].

In conclusion, the present studies highlight similar alterations of pancreatic islet cell differentiation in three well-characterised mouse models of beta-cell loss, insulin resistance and diabetes that exhibit contrasting aetiologies. As such, STZ, HFF and HC mice presented with increased beta- to alpha-cell transdifferentiation, demonstrating this process as an authentic characteristic associated with diabetes. Notably, liraglutide, and to lesser extent sitagliptin, exerted positive effects on beta-cell transdifferentiation particularly in STZ and HFF mice, as well as promoting growth and survival of these cells. Such actions emphasise
the potential of incretin enhancer drugs for beta-cell restoration and subsequent promotion of enduring benefits in diabetes.

Author contribution

NI, CRM and PRF conceived the study, participated in the analysis and interpretation of data, drafted the manuscript and revised it critically for intellectual content. NT participated in the analysis and interpretation of data, drafted the manuscript and revised it critically for intellectual content. All authors approved the final version of the manuscript. NT is the guarantor of this work.

Declaration of interest

All authors declare no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

These studies were supported by a Department for the Economy, Northern Ireland, PhD Research Scholarship (NT) and an early career research award from Diabetes UK to RCM. Additional support (PRF and NI) was provided by Ulster University selective research funding.
References


Gault VA, Lennox R & Flatt PR 2015 Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline *Diabetes, Obesity and Metabolism* **17** 403-413.


Ghanim H, Green K & Dandona P 2019 Liraglutide and Dapagliflozin Induce an Increase in Plasma GLP-1 and GLP-2 Concentrations. *Diabetes* **68**(S1) 1034-P.


Li Y, Cao X, Li L, Brubaker PL, Edlund H & Drucker DJ 2005 β-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like-peptide-1. Diabetes 54 482-491.


Porter D, Kerr B, Flatt P, Holscher C & Gault V 2010 Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes, Obesity and Metabolism 12 891-899.


Souza-Mello V, Gregório BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB & Mandarim-de-Lacerda CA 2010 Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and
pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clinical Science 119 239-250.


Taylor BL, Benthuyzen J & Sander M 2015 Postnatal β-cell proliferation and mass expansion is dependent on the transcription factor Nkx6.1. Diabetes 64 897-903.


van der Meulen T & Huiing MO 2015 Role of transcription factors in the transdifferentiation of pancreatic islet cells. Journal of Molecular Endocrinology 54 R103-17.


Figure 1. Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration, on body weight and energy intake in Ins1\textsuperscript{Cre+/Rosa26-eYFP} mice. Body weight, percentage body weight change and energy intake was measured during and after 10 or 12 days, as appropriate, treatment with saline vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.) in (A,B,C) STZ, (D,E,F) HFF and (G,H,I) HC Ins1\textsuperscript{Cre+/Rosa26-eYFP} diabetic mice. Values represent mean ± SEM for 6 mice. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. ΔP<0.05, ΔΔP<0.01. ΔΔΔP<0.001 compared to respective STZ, HFF or HC controls.

Figure 2. Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration, on non-fasting circulating glucose, insulin and glucagon as well as pancreatic insulin and glucagon content in Ins1\textsuperscript{Cre+/Rosa26-eYFP} mice. Blood glucose was assessed in (A) STZ, (B) HFF and (C) HC Ins1\textsuperscript{Cre+/Rosa26-eYFP}
diabetic mice for 3 days prior to, and 10 or 12 days during, as appropriate, treatment with saline vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). (D-H) Final circulating (D) blood glucose as well as plasma and pancreatic (E,F) insulin or (G,H) glucagon were measured at the end of the treatment period. Values represent mean ± SEM for 6 mice. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. ∆P<0.05, ∆∆P<0.01. ∆∆∆P<0.001 compared to respective STZ, HFF or HC controls.

Figure 3. Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration, on pancreatic morphology in Ins1<sup>Cre<sup>+</sup>/Rosa26-eYFP</sup> mice. (A-C) Parameters were assessed in STZ, HFF and HC Ins1<sup>Cre<sup>+</sup>/Rosa26-eYFP</sup> diabetic mice after 10 or 12 days, as appropriate, treatment with saline vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). (A) Islet, (B) beta- and (C) alpha-cell areas were measured using CellF<sup>®</sup> image analysis software. (D) Representative images (40X) of islets showing insulin (red), glucagon (green) and DAPI (blue) immunoreactivity from each group of mice. Values are mean ± SEM for 6 mice, with approximately 80 islets per group analysed. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. ∆P<0.05, ∆∆P<0.01 compared to respective STZ, HFF or HC controls.

Figure 4. Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration, on pancreatic beta-cell lineage and Pdx1 expression in Ins1<sup>Cre<sup>+</sup>/Rosa26-eYFP</sup> mice. (A-C) Parameters were assessed in STZ, HFF and HC Ins1<sup>Cre<sup>+</sup>/Rosa26-eYFP</sup> diabetic mice after 10 or 12 days, as appropriate, treatment with saline vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). (D-F) Representative images (40X) of islets showing (D) insulin (red), (E) glucagon (red) and (D,E) GFP (green), or (F) insulin (red) and Pdx1 (green) immunoreactivity from each group
of mice. Arrows indicate co-staining, as appropriate. Values are mean ± SEM for 6 mice, with approximately 80 islets per group analysed. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. ^P<0.05, ^AP<0.01. ^^AP<0.001 compared to respective STZ, HFF or HC controls.

Figure 5. Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration, on pancreatic beta- and alpha-cell apoptosis in Ins1Cre+/Rosa26-eYFP mice. (A,B) Parameters were assessed in STZ, HFF and HC Ins1Cre+/Rosa26-eYFP diabetic mice after 10 or 12 days, as appropriate, treatment with saline vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). Pancreatic (A) beta- and (B) alpha-cell apoptosis were measured using TUNEL staining and quantified with ImageJ software. (C,D) Representative images (40X) of islets showing insulin or glucagon (both green), Ki-67 (red) and DAPI (blue) immunoreactivity from each group of mice. Arrows indicate co-staining, as appropriate. Values are mean ± SEM for 6 mice, with approximately 80 islets per group analysed. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. ^P<0.05, ^AP<0.01. ^^AP<0.001 compared to respective STZ, HFF or HC controls.

Figure 6. Effects of STZ-, HFF- and HC-treatment alone, and in combination with liraglutide or sitagliptin administration, on pancreatic beta- and alpha-cell proliferation in Ins1Cre+/Rosa26-eYFP mice. (A,B) Parameters were assessed in STZ, HFF and HC Ins1Cre+/Rosa26-eYFP diabetic mice after 10 or 12 days, as appropriate, treatment with saline vehicle, liraglutide (25 nmol/kg bw, i.p.; B.I.D) or sitagliptin (50 mg/kg, p.o.). Pancreatic (A) beta- and (B) alpha-cell proliferation were measured using Ki-67 staining and quantified with ImageJ software. (C,D) Representative images (40X) of islets showing insulin or glucagon
(both green), Ki-67 (red) and DAPI (blue) immunoreactivity from each group of mice. Arrows indicate co-staining, as appropriate. Values are mean ± SEM for 6 mice, with approximately 80 islets per group analysed. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. ∆P<0.05, ∆∆P<0.01. ∆∆∆P<0.001 compared to respective STZ, HFF or HC controls.
Table 1. Target, host, dilution factors and source of primary and secondary antibodies employed for immunofluorescent studies

<table>
<thead>
<tr>
<th>Primary Antibodies</th>
<th>Target</th>
<th>Host</th>
<th>Dilution</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin</td>
<td>Mouse</td>
<td>1:400</td>
<td>Abcam (ab6995)</td>
<td></td>
</tr>
<tr>
<td>Glucagon</td>
<td>Guinea-pig</td>
<td>1:400</td>
<td>Raised in-house (PCA2/4)</td>
<td></td>
</tr>
<tr>
<td>GFP</td>
<td>Goat</td>
<td>1:1000</td>
<td>Abcam (ab5450)</td>
<td></td>
</tr>
<tr>
<td>Ki-67</td>
<td>Rabbit</td>
<td>1:500</td>
<td>Abcam (ab15580)</td>
<td></td>
</tr>
<tr>
<td>Pdx-1</td>
<td>Guinea-pig</td>
<td>1:200</td>
<td>Abcam (ab47308)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secondary Antibodies</th>
<th>Target</th>
<th>Host</th>
<th>Reactivity</th>
<th>Dilution</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG, Alexa Fluor 594</td>
<td>Goat</td>
<td>Mouse</td>
<td>1:400</td>
<td>Invitrogen, UK</td>
<td></td>
</tr>
<tr>
<td>IgG, Alexa Fluor 488</td>
<td>Goat</td>
<td>Mouse</td>
<td>1:400</td>
<td>Invitrogen, UK</td>
<td></td>
</tr>
<tr>
<td>IgG, Alexa Fluor 594</td>
<td>Goat</td>
<td>Guinea-pig</td>
<td>1:400</td>
<td>Invitrogen, UK</td>
<td></td>
</tr>
<tr>
<td>IgG, Alexa Fluor 488</td>
<td>Goat</td>
<td>Guinea-pig</td>
<td>1:400</td>
<td>Invitrogen, UK</td>
<td></td>
</tr>
<tr>
<td>IgG, Alexa Fluor 594</td>
<td>Goat</td>
<td>Rabbit</td>
<td>1:400</td>
<td>Invitrogen, UK</td>
<td></td>
</tr>
<tr>
<td>IgG, Alexa Fluor 488</td>
<td>Goat</td>
<td>Rabbit</td>
<td>1:400</td>
<td>Invitrogen, UK</td>
<td></td>
</tr>
<tr>
<td>IgG, Alexa Fluor 488</td>
<td>Donkey</td>
<td>Goat</td>
<td>1:400</td>
<td>Invitrogen, UK</td>
<td></td>
</tr>
</tbody>
</table>
Figure 2

(A) Blood Glucose - STZ
(B) Blood Glucose - HFF
(C) Blood Glucose - HC

(D) Final Blood Glucose
(E) Plasma Insulin
(F) Pancreatic Insulin Content

(G) Plasma Glucagon
(H) Pancreatic Glucagon Content

Copyright © 2019 Society for Endocrinology
Figure 3

(A) Islet Area

(B) Beta Cell Area

(C) Alpha Cell Area

(D) Lean Control

STZ Control

STZ + Liraglutide

STZ + Sitagliptin

HFF Control

HFF + Liraglutide

HFF + Sitagliptin

HC Control

HC + Liraglutide

HC + Sitagliptin

Insulin / Glucagon / DAPI

Copyright © 2019 Society for Endocrinology
### Figure 4

#### (A) Insulin⁺⁺⁺, GFP⁺⁺⁺ Cells

<table>
<thead>
<tr>
<th>Control</th>
<th>Treatment</th>
<th>% Insulin⁺⁺⁺, GFP⁺⁺⁺ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lean Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STZ Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STZ + Liraglutide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STZ + Sitagliptin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFF Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFF + Liraglutide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFF + Sitagliptin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC + Liraglutide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC + Sitagliptin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### (B) Glucagon⁺⁺⁺, GFP⁺⁺⁺ Cells

<table>
<thead>
<tr>
<th>Control</th>
<th>Treatment</th>
<th>% Glucagon⁺⁺⁺, GFP⁺⁺⁺ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lean Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STZ Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STZ + Liraglutide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STZ + Sitagliptin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFF Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFF + Liraglutide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFF + Sitagliptin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC + Liraglutide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC + Sitagliptin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### (C) Insulin⁺⁺⁺, Pdx1⁺⁺⁺ cells

<table>
<thead>
<tr>
<th>Control</th>
<th>Treatment</th>
<th>% Insulin⁺⁺⁺, Pdx1⁺⁺⁺ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lean Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STZ Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STZ + Liraglutide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STZ + Sitagliptin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFF Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFF + Liraglutide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HFF + Sitagliptin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC + Liraglutide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC + Sitagliptin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### (D) Insulin / GFP / DAPI

- Lean Control
- STZ Control
- HFF Control
- HC Control
- STZ + Liraglutide
- STZ + Sitagliptin
- HFF + Liraglutide
- HFF + Sitagliptin
- HC + Liraglutide
- HC + Sitagliptin

#### (E) Glucagon / GFP / DAPI

- Lean Control
- STZ Control
- HFF Control
- HC Control
- STZ + Liraglutide
- STZ + Sitagliptin
- HFF + Liraglutide
- HFF + Sitagliptin
- HC + Liraglutide
- HC + Sitagliptin

#### (F) Insulin / PDX1 / DAPI

- Lean Control
- STZ Control
- HFF Control
- HC Control
- STZ + Liraglutide
- STZ + Sitagliptin
- HFF + Liraglutide
- HFF + Sitagliptin
- HC + Liraglutide
- HC + Sitagliptin
Figure 5

(A) Beta Cell Apoptosis

(B) Alpha Cell Apoptosis

(C) Insulin / TUNEL

(D) Glucagon / TUNEL

% Beta cells expressing TUNEL
% Alpha cells expressing TUNEL

Lean Control STZ Control STZ + Liraglutide STZ + Sitagliptin
HFF Control HFF + Liraglutide HFF + Sitagliptin
HC Control HC + Liraglutide HC + Sitagliptin

Copyright © 2019 Society for Endocrinology

Downloaded from Bioscientifica.com at 01/30/2020 11:46:36AM via Univ of Ulster At Coleraine
Figure 6

(A) Beta cell proliferation

(B) Alpha cell proliferation

(C) Ki67 / Insulin / DAPI

(D) Ki67 / Glucagon / DAPI

Copyright © 2019 Society for Endocrinology